Formycon AG

Formycon AG is a German biopharmaceutical company headquartered in Planegg/Martinsried, Germany, established in 2012. It is a publicly traded company on the Frankfurt Stock Exchange (XETRA) under the ticker FYB, with a market capitalization of approximately €0.39 billion as of May 2026. The company employs over 240 people.

Formycon specializes in the development of high-quality biosimilar medicines, which are follow-on products of existing biopharmaceutical drugs. Their focus areas include ophthalmology, immunology, and other chronic diseases. Formycon covers the entire value chain from technical-pharmaceutical development and clinical trials to regulatory approval and commercialization support through strategic partnerships. Their product portfolio includes approved biosimilars like FYB201 (ranibizumab), FYB202 (ustekinumab), and FYB203 (aflibercept), with additional candidates such as FYB206 (pembrolizumab) and FYB208 (dupilumab) in development. The company reported preliminary group revenues of approximately €45 million for the 2025 fiscal year.

Formycon AG's patent litigation posture is that of an operating company defending its biosimilar products. The company is tracked in one case as a defendant and zero as a plaintiff. This single tracked case, Regeneron Pharmaceuticals, Inc. v. Formycon AG, indicates they are typically challenged by originator drug companies seeking to protect their intellectual property. The litigation has involved venues such as the U.S. District Court for the Northern District of West Virginia, the U.S. Court of Appeals for the Federal Circuit, and the PTAB.

A notable aspect of Formycon's litigation is the ongoing dispute with Regeneron Pharmaceuticals concerning biosimilar versions of Regeneron's EYLEA (aflibercept) product. Formycon and its partners have engaged in patent litigation in both the U.S. and Europe. In the U.S., a settlement allows Formycon to launch its aflibercept biosimilar (AHZANTIVE) in the fourth quarter of 2026. In Europe, a settlement with Regeneron and Bayer in March 2026 permits the launch of AHZANTIVE and BAIAMA aflibercept biosimilars in May 2026. These cases highlight Formycon's efforts to bring biosimilar versions of high-revenue biologics to market by navigating complex patent landscapes.